文献速递前列腺癌

预测MRI引导活检时需同步系统穿刺的临床工具

A clinical prediction tool to determine the need for concurrent systematic sampling at the time of magnetic resonance imaging-guided biopsy.
PubMed 文献 · BJU Int · 2018-12-01

本研究基于398例接受TRUS/MRI融合引导活检并同步系统穿刺的男性,开发临床预测工具以评估省略系统穿刺漏诊显著前列腺癌的风险。结果显示46例(11.6%)显著癌仅见于系统穿刺,模型区分度良好(C指数0.70),阈值概率<30%时净临床获益优于全部或省略穿刺。

要点

  • 省略同步系统穿刺会漏诊超过1/10的显著前列腺癌。
  • 临床情境、MRI病灶数目和最高PI-RADS评分可预测系统穿刺独有显著癌。
  • 预测模型区分度良好(C指数0.70),但需外部验证后用于临床。

核心结论

  • 省略同步系统穿刺会漏诊超过十分之一的显著前列腺癌,预测模型可改善患者选择。

研究设计与样本

  • 连续纳入接受TRUS/MRI融合引导活检且同步系统穿刺的男性,共398例。

主要发现

  • 46例(11.6%)显著癌(Gleason评分≥3+4)仅见于系统穿刺而未见于靶向穿刺。
  • 临床情境、MRI病灶数目和最高PI-RADS评分是系统穿刺独有显著癌的预测因素。
  • 模型区分度良好,C指数为0.70。
  • 决策曲线分析显示阈值概率<30%时模型净临床获益高于全部穿刺或全部省略穿刺。

关键数值与推荐

  • 显著癌定义为Gleason评分≥3+4。
  • 模型C指数为0.70,阈值概率<30%时净临床获益更优。

临床怎么用

  • 可用于筛选接受TRUS/MRI融合引导活检的患者中谁应同步进行系统穿刺,以减少漏诊显著癌。

局限性

  • 模型需在外部队列中验证后方可用于常规临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop a clinical prediction tool that characterises the risk of missing significant prostate cancer by omitting systematic biopsy in men undergoing transrectal ultrasonography/magnetic resonance imaging (TRUS/MRI)-fusion-guided biopsy. PATIENTS AND METHODS: A consecutive sample of men undergoing TRUS/MRI-fusion-guided biopsy with the UroNav® system (Invivo International, Best, The Netherlands) who also underwent concurrent systematic biopsy was included. By comparing the grade of cancer diagnosed on targeted and systematic biopsy cores, we identified cases where clinically significant disease (Gleason score ≥3+4) was only found on systematic and not targeted cores. Multivariable logistic regression analyses were used to identify predictive factors for finding significant cancer on systematic cores only. We then used these data to develop a nomogram and evaluated its utility using decision curve analysis. RESULTS: Of the 398 men undergoing TRUS/MRI-fusion-guided biopsy in our study, there were 46 (11.6%) cases in which clinically significant cancer was missed on targeted biopsy and detected on systematic biopsy. The clinical setting, number of MRI lesions identified, and the highest Prostate Imaging-Reporting and Data System (PI-RADS) score of the lesions, were all found to be predictors of this. Our model had a good discriminative ability (concordance index = 0.70). The results from our decision curve analysis show that this model provides a higher net clinical benefit than either biopsying all men or omitting biopsy in all patients when the threshold probability is <30%. CONCLUSION: We found that omitting concurrent systematic biopsy in men undergoing TRUS/MRI-fusion-guided biopsy would miss significant disease in more than one in 10 patients. We propose a prediction model with good discriminative ability that can be used to improve patient selection for performing concurrent systematic biopsy in order to minimise the number of missed significant cancers. It is important that our model is validated in external cohorts before being employed in routine clinical practice.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Sathianathen NJ, Warlick CA, Weight CJ, et al. A clinical prediction tool to determine the need for concurrent systematic sampling at the time of magnetic resonance imaging-guided biopsy. BJU Int. 2018. PMID: 30417504. doi:10.1111/bju.14617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。